Immunovant, Inc. (IMVT), a subsidiary of Roivant (ROIV), Tuesday reported positive initial data from the Phase 1 study of its drug candidate IMVT-1402 for the treatment of Immunoglobulin G (IgG)-mediated autoimmune diseases.
The Phase 1 trial is an ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IMVT-1402 in healthy adults.
In the single-ascending dose (SAD) portion of the Phase 1 study IMVT-1402 demonstrated consistent reduction in IgG, the company said.
Further, initial results from the multiple-ascending dose (MAD) study showed that after four weekly 300 mg doses IMVT-1402, the mean total IgG reduction from baseline was 63%, with no decrease in serum albumin below baseline and no increase in LDL-C above baseline observed. The company said dosing for the 600 mg cohort has recently begun.
Additional data from MAD study are expected in November.
For comments and feedback: editorial@rttnews.com